Dexrazoxane for anthracycline extravasation.

Article Details


Langer SW

Dexrazoxane for anthracycline extravasation.

Expert Rev Anticancer Ther. 2007 Aug;7(8):1081-8.

PubMed ID
18028016 [ View in PubMed

Accidental extravasation of anthracycline-containing anticancer chemotherapy is a feared complication that may lead to progressive tissue damage. The condition may require extensive surgical intervention and often has severe long-term effects. Until a short while ago, there has been no effective treatment against the devastating effect of extravasated anthracycline. However, dexrazoxane has proven highly effective in preventing necrosis in both preclinical and clinical studies and is now approved in Europe (Savene), and has orphan drug status in the USA (Totect) for this indication. Hence, it is the first and only proven effective antidote against anthracycline extravasation injuries.

DrugBank Data that Cites this Article